We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-20.31%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$268M
AUM Growth
-$125M
Cap. Flow
-$27.2M
Cap. Flow %
-10.13%
Top 10 Hldgs %
57.14%
Holding
61
New
14
Increased
11
Reduced
11
Closed
14

Top Buys

Rank Stock Value
1
AVTX icon
Avalo Therapeutics
AVTX
+$8.46M
2
EPZM
Epizyme, Inc
EPZM
+$7.06M
3
IMGN
Immunogen Inc
IMGN
+$6.2M
4
ABEO icon
Abeona Therapeutics
ABEO
+$3.93M
5
AIMT
Aimmune Therapeutics
AIMT
+$3.88M

Top Sells

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$10M
2
AMAG
AMAG Pharmaceuticals
AMAG
+$8.4M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$7.01M
4
AMRN
Amarin Corp
AMRN
+$6.38M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$6.11M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IOVA icon
51
Iovance Biotherapeutics
IOVA
$3.74B
– –
-325,000
Closed -$3.66M
OCUL icon
52
Ocular Therapeutix
OCUL
$2.38B
– –
-800,000
Closed -$5.5M
RARE icon
53
Ultragenyx Pharmaceutical
RARE
$2.59B
– –
-80,000
Closed -$6.11M
XENE icon
54
Xenon Pharmaceuticals
XENE
$6B
– –
-465,200
Closed -$7.01M
TVRD
55
Tvardi Therapeutics
TVRD
$24M
– –
-3,611
Closed -$3.11M
INFI
56
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-275,000
Closed -$745K
BFRA
57
DELISTED
Biofrontera AG American Depositary Shares
BFRA
– –
-79,007
Closed -$1.07M
AMAG
58
DELISTED
AMAG Pharmaceuticals
AMAG
– –
-420,000
Closed -$8.4M
FOMX
59
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
– –
-91,000
Closed -$521K
ACHN
60
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-275,000
Closed -$1.01M
CORI
61
DELISTED
Corium International, Inc.
CORI
– –
-550,000
Closed -$5.23M
1 2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2018 Portfolio in Review

As of Q4 2018, Opaleye Management held 61 positions worth $268M, down 32% from $393M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Opaleye Management withdrew a net $27.2M in Q4 2018, closing 14 positions and reducing 11 holdings. Its most notable exit was Agios Pharmaceuticals, an estimated $10M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Opaleye Management opened a new position in Avalo Therapeutics worth $6.21M.

  • Opaleye Management's largest Q4 2018 buy was Avalo Therapeutics: 759 shares worth $6.21M.
  • Opaleye Management added most to Epizyme, Inc in Q4 2018, an estimated $7.06M increase.
  • Opaleye Management's biggest Q4 2018 reduction was Amarin Corp, cutting an estimated $6.38M.
  • Opaleye Management fully exited Agios Pharmaceuticals in Q4 2018, selling an estimated $10M.
  • Opaleye Management's ten largest holdings make up 57% of its $268M portfolio in Q4 2018.
  • Opaleye Management opened 14 new positions and closed 14 in Q4 2018.
  • Opaleye Management's portfolio value fell 32% quarter-over-quarter to $268M.

Based on Opaleye Management's 13F filing for Q4 2018, filed 14 Feb 2019.